

VEGF receptor, wherein the first receptor is KDR and the second receptor is Flt-4.

III. Claims 4, 19-23, 28, 31, 34, drawn to an antibody having a first antigen binding site specific for a first VEGF receptor and a second antigen binding site specific for a second VEGF receptor, wherein the first receptor is Flt-1 and the second receptor is Flt-4.

IV. Claims 36-40, drawn to a method for making an antibody having a first antigen binding site comprising a first immunoglobulin heavy chain variable domain and a first immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a first VEGF receptor, and a second antigen binding site comprising a second immunoglobulin heavy chain variable domain and a second immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a second VEGF receptor, wherein the first receptor is KDR and the second receptor is Flt-1.

V. Claims 36-40, drawn to a method for making an antibody having a first antigen binding site comprising a first immunoglobulin heavy chain variable domain and a first immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a first VEGF receptor, and a second antigen binding site comprising a second immunoglobulin heavy chain variable domain and a second immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a second VEGF receptor, wherein the first receptor is KDR and the second receptor is Flt-4.

VI. Claims 36-40, drawn to a method for making an antibody having a first antigen binding site comprising a first immunoglobulin heavy chain variable domain and a first immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a first VEGF receptor, and a second antigen binding site comprising a second immunoglobulin heavy chain variable domain and a second immunoglobulin light chain variable domain that specifically binds to an extracellular domain of a second VEGF receptor, wherein the first receptor is Flt-1 and the second receptor is Flt-4.

VII. Claims 41-43, drawn to a method for neutralizing activation of a first VEGF receptor and a second VEGF receptor in a cell, a method of reducing tumor growth in a mammal in need thereof, and a method for inhibiting angiogenesis in a mammal in need thereof which comprises treating a cell with an antibody having a first antigen binding site specific for the first VEGF receptor and a second binding site specific for the second VEGF receptor in an amount sufficient to neutralize activation of the receptors wherein the first receptor is KDR and the second receptor is Flt-1.

VIII. Claims 41-43, drawn to a method for neutralizing activation of a first VEGF receptor and a second VEGF receptor in a cell, a method of reducing tumor growth in a mammal in need thereof, and a method for inhibiting angiogenesis in a mammal in need thereof which comprises treating a cell with an antibody having a first antigen binding site specific for the first VEGF receptor and a second binding site specific for the second VEGF receptor in an amount sufficient to neutralize activation of the receptors wherein the first receptor is KDR and the second receptor is Flt-4.

IX. Claims 41-43, drawn to a method for neutralizing activation of a first VEGF receptor and a second VEGF receptor in a cell, a method of reducing tumor growth in a mammal in need thereof, and a method for inhibiting angiogenesis in a mammal in need thereof which comprises treating a cell with an antibody having a first antigen binding site specific for the first VEGF receptor and a second binding site specific for the second VEGF receptor in an amount sufficient to neutralize activation of the receptors wherein the first receptor is Flt-1 and the second receptor is Flt-4.

In response, Applicants hereby elect the invention of Group VII, corresponding to claims 41-43 wherein the first receptor is KDR and the second receptor is Flt-1. Applicants reserve the right to file a divisional application corresponding to the non-elected claims.

The Examiner has indicated that any election of claims in response to the outstanding restriction requirement must also include election of a single disclosed combination of six CDRs for the heavy and light chain variable domains of the antigen binding sites specific for both first and second VEGF receptors. Applicants respectfully submit that elected claims 41-43 are generic and allowable as such, however, Applicants further elect herein SEQ ID NOs: 1-6 which correspond to the amino acid sequences of the CDRs for the first VEGF receptor, KDR (see Claim 6) and SEQ ID NOs: 35-40 which correspond to the amino acid sequences of the CDRs for the second VEGF receptor, Flt-1 (see Claim 19).


Application No.: 10/520,026

Docket No.: IMCLON 3.3-002 II

In the event any fee is due in connection with the present response, the Examiner is authorized to charge Deposit Account No. 12-1095 therefore.

Dated: April 17, 2009

Respectfully submitted,

By 

Diane P. Tso

Registration No.: 46,012
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant

999272_1.DOC